Oncology is the costliest disease-state to treat. Spending on all medicines used in the treatment of patients with cancer reached nearly $150 billion in 2018 up 12.9% for the year, marking the fifth consecutive year of double-digit growth.
Much has been said regarding utilization management being a burden to providers, patients, and the healthcare system, yet even the Centers for Medicare and Medicaid Services (CMS) acknowledges that the use of prior authorization tools has great value to ensuring claims meet required guidelines.
In this webinar, industry leaders will discuss approaches for oncology prior authorization, which can simultaneously help bend the oncology drug cost curve while improving treatment options.
During this webinar, the following topics will be explored:
- Insights for health plans thinking about building or partnering for oncology drug utilization management, specifically, how to create a program that provides value to both members and network providers.
- How prior authorization for oncology should be viewed in comparison to other diseases and medical procedures, considering the cost and complexity of cancer drug treatments.
- The role of value-based care payment models for oncology drug spend.
- How to proactively address the rising tide of new cancer drugs entering the market and the potential financial burden this creates for patients, providers, and health plans.